Roche (RHHBY) announced data on its pipeline candidate ACE910 at the 56th American Society of Hematology.
ACE910 is an antibody therapy being evaluated for treating haemophilia A patients.
Roche reported results from a phase I study on ACE910 wherein it was observed that once-weekly subcutaneous administration of ACE910 was well tolerated and showed a promising efficacy profile in hemophilia A patients.
The objectives of the phase I study were to assess the safety and efficacy of ACE910 in this patient group, as well as the pharmacokinetics and pharmacodynamics of the candidate.
Additionally, results showed that ACE910 significantly reduced the annualized bleeding rate during treatment, compared to the same in the six-month period prior to study enrollment.
Moreover, ACE910 was effective in reducing the rate of bleeding in spite of the presence of blood clotting factor VIII in the patient’s blood.
Hence, Roche plans to move the candidate into advanced clinical trials in 2015 based on final results from the phase I study.
We are encouraged by Roche’s performance so far in 2014. The oncology portfolio looks solid as ever and we expect further traction. We are also impressed by the company's efforts to grow its portfolio beyond oncology to immunology and ophthalmology. However, generic competition for Xeloda and Pegasys will negatively impact sales going forward.
Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader health care sector include AbbVie (ABBV), Allergan (AGN) and Biodel Inc. (BIOD). All three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment